COB Columbia Laboratories

Columbia Laboratories to Hold Conference Call on Third Quarter 2003 Financial Results LIVINGSTON, N.J., Nov. 7 /PRNewswire-FirstCall/ -- Columbia Laboratories will be holding a conference call on November 12, 2003 at 8:30 AM ET to review third quarter 2003 financial results. Fred Wilkinson, Columbia's chairman, president and chief executive officer, and David Weinberg, Columbia's chief financial officer, will review new corporate and clinical developments. The U.S./Canada dial-in number is 877-407-8031. The international dial-in number is 201-689-8031. A recording of the conference call will be available two hours after completion, and will be available until November 19, 2003 at 11:59 PM ET at 877-660-6853 (U.S.) and 201-612-7415. The conference account number is 1628, and the ID number is 81831. The call will be webcast on the Columbia Laboratories Web site, and will be available until February 12, 2004 at 11:59 PM ET at http://www.columbialabs.com/ About Columbia Laboratories Columbia Laboratories, Inc. is a U.S.-based international pharmaceutical company dedicated to research and development of women's health care and endocrinology products, including those intended to treat infertility, dysmenorrhea, endometriosis and hormonal deficiencies. Columbia has introduced Striant(TM) (testosterone buccal system) for treatment of hypogonadism in men. Columbia's products primarily utilize the Company's patented Bioadhesive Delivery System (BDS) technology. For more information, please visit http://www.columbialabs.com/. This press release contains statements that constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Those statements include statements regarding the intent, belief or current expectations of the company and its management team. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those projected in the forward-looking statements. Such risks and uncertainties include, among other things, the successful marketing of existing products, including Striant(TM) (testosterone buccal system), Prochieve(R) 8% (progesterone gel), Prochieve(R) 4% (progesterone gel), RepHresh(R) Vaginal Gel, and Advantage-S(R) Contraceptive Gel; timely and successful development of new products; timely and successful completion of clinical studies; success in obtaining acceptance and approval of new products by the FDA and international regulatory agencies; and competitive economic and regulatory factors in the pharmaceutical and health care industry; general economic conditions; and other risks and uncertainties that may be detailed, from time-to-time, in Columbia's reports filed with the Securities and Exchange Commission. DATASOURCE: Columbia Laboratories, Inc. CONTACT: Investors - Ritu Baral of The Trout Group, +1-212-477-9007, ext. 25, for Columbia Laboratories, Inc.; James Apostolakis, Vice Chairman, +1-212-588-1900, or David Weinberg, Chief Financial Officer, +1-973-994-3999, both of Columbia Laboratories, Inc. Web site: http://www.columbialabs.com/

Copyright